References
- Camu W, Henderson CE. Rapid purification of embryonic rat motor neurons: an in vitro model for studying MND/ALS pathogenesis. J Neurol Sci 1994; 124(suppl): 73–74.
- Rothstein JD, Jin L, Dykes-Hoberg M et al. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993; 90: 6591–6595.
- Henderson CE. Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis: potential and pitfalls. Adv Neurol 1995; 68: 235–240.
- Wong PC, Pardo CA, Borchelt DR et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14: 1105–1116.
- Bruijn LI, Becher MW, Lee MK et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327–338.
- Gurney ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994; 264: 1772–1775.
- Howland DS, Liu J, She Y et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 2002; 99: 1604–1609.
- Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806–819.
- Gong YH, Parsadanian AS, Andreeva A et al. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motor neuron degeneration. J Neurosci 2000; 20: 660–665.
- Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutants in postnatal motor neurons does not cause motor neuron pathology or motor neuron disease. J Neurosci 2002; 22: 4825–4832.
- Raoul C, Estevez AG, Nishimune H et al. Motor neuron death triggered by a specific pathway downstream of Fas. Potentiation by ALS-linked SOD1 mutations. Neuron 2002; 35: 1067–1083.
- Ferrante RJ, Andreassen OA, Jenkins BG et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease. J Neurosci 2000; 20: 4389–4397.
- Gurney ME, Cutting FB, Zhai P et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147–157.
- Groeneveld GJ, Veldink JH, van der Tweel I. A randomized sequential trial of creatine monohydrate in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–445.
- Kriz J, Gowing G, Julien J. An efficient three-drug cocktail for motor neuron disease induced by mutant superoxide dismutase. Ann Neurol 2003; 53: 429–436.
- Chen M, Ona VO, Li M et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington’s disease. Nat Med 2000; 6: 797–801.
- Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 268–278.
- Van den BL, Tilkin P, Lemmens G et al. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002; 13: 1067–1070.
- Heemskerk J, Tobin AJ, Ravina B. From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials. Nat Neurosci 2002; 5(suppl): 1027–1029.